Google Cloud's updated its Vertex AI platform to support AI agents with including the Agent Development Kit, the Agent2Agent ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research note updating estimates within the firm’s ...

In a report released today, Chris Quintero from Morgan Stanley maintained a Buy rating on Vertex (VERX – Research Report), with a price target of $55.00. Discover outperforming stocks and invest ...

Previously, Veo 2 was only available to a select group of Vertex AI users ... clicking the down arrow next to the Gemini Advanced logo and selecting Veo 2 from the list of models.

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

KING OF PRUSSIA, Pa., April 14, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading global technology provider of indirect tax solutions, today announced that it will release first ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...